Form 8-K - Current report:
SEC Accession No. 0001437749-25-030631
Filing Date
2025-10-07
Accepted
2025-10-07 16:06:05
Documents
14
Period of Report
2025-10-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K EARNINGS iccc20251007_8k.htm   iXBRL 8-K 32809
2 EXHIBIT 99.1 ex_867237.htm EX-99.1 20563
  Complete submission text file 0001437749-25-030631.txt   189420

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA iccc-20251007.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE iccc-20251007_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE iccc-20251007_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iccc-20251007_pre.xml EX-101.PRE 11584
16 EXTRACTED XBRL INSTANCE DOCUMENT iccc20251007_8k_htm.xml XML 2832
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 251379878
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)